The inflammatory microenvironment of the lung at the time of infection governs innate control of SARS-CoV-2 replication

Paul J. Baker,Andrea C. Bohrer,Ehydel Castro,Eduardo P. Amaral,Maryonne Snow-Smith,Flor Torres-Juárez,Sydnee T. Gould,Artur T. L. Queiroz,Eduardo R. Fukutani,Cassandra M. Jordan,Jaspal S. Khillan,Kyoungin Cho,Daniel L. Barber,Bruno B. Andrade,Reed F. Johnson,Kerry L. Hilligan,Katrin D. Mayer-Barber
DOI: https://doi.org/10.1101/2024.03.27.586885
2024-03-27
Abstract:SARS-CoV-2 infection leads to vastly divergent clinical outcomes ranging from asymptomatic infection to fatal disease. Co-morbidities, sex, age, host genetics and vaccine status are known to affect disease severity. Yet, how the inflammatory milieu of the lung at the time of SARS-CoV-2 exposure impacts the control of viral replication remains poorly understood. We demonstrate here that immune events in the mouse lung closely preceding SARS-CoV-2 infection significantly impact viral control and we identify key innate immune pathways required to limit viral replication. A diverse set of pulmonary inflammatory stimuli, including resolved antecedent respiratory infections with or influenza, ongoing pulmonary infection, ovalbumin/alum-induced asthma or airway administration of defined TLR ligands and recombinant cytokines, all establish an antiviral state in the lung that restricts SARS-CoV-2 replication upon infection. In addition to antiviral type I interferons, the broadly inducible inflammatory cytokines TNFα and IL-1 precondition the lung for enhanced viral control. Collectively, our work shows that SARS-CoV-2 may benefit from an immunologically quiescent lung microenvironment and suggests that heterogeneity in pulmonary inflammation that precedes or accompanies SARS-CoV-2 exposure may be a significant factor contributing to the population-wide variability in COVID-19 disease outcomes.
Immunology
What problem does this paper attempt to address?